Gilead's remdesivir reduces COVID-19 mortality risk- data

Gilead Sciences Inc (GILD.O) said an analysis showed its antiviral remdesivir reduced mortality rates in hospitalized patients with COVID-19 and increased the likelihood of being discharged by day 28 after a five-day course of the treatment. The drugmaker said on Monday it analyzed data from 98,654 patients from three retrospective studies of the real-world treatment of hospitalized COVID-19 patients.